Pilot Study for Evaluating the Role of F-18 FLT PET/CT in Therapeutic Decision Making in Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms
Conditions: Keywords
lung cancer, F-18 FLT PET/CT
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case-Only, Time Perspective: Prospective
Intervention
Name: PET/CT
Type: Other
Overall Status
Not yet recruiting
Summary
The objective of this pilot study is to determine whether 18F-FLT PET/CT can predict which patients will have poorer progression free survival and overall survival in advanced Non-small Cell Lung Cancer (NSCLC) after first-line therapy and, therefore, need more aggressive treatment.
Detailed Description
Standard therapy for patients with advanced NSCLC is platinum based doublet chemotherapy. Current first-line chemotherapy is usually limited to 4-6 cycles, as prolonging treatment does not result in additional benefit and may often cause further toxicity. Until recently, treatment guidelines recommended withholding administration of later-line systemic anti-cancer treatment until disease progression.

There are several reports suggesting that maintenance therapy following first-line chemotherapy offers improved survival in advance stage patients. This approach involves the administration of an active treatment immediately after first-line chemotherapy, thus maintaining the clinical benefit initially obtained. However, drug related toxicity and costs are of great concern. There may also be patients with less aggressive disease where an immediate transition to maintenance therapy after first-line results in overtreatment.

Therefore, selecting patients who require more aggressive treatment or earlier intervention is necessary.

If FLT PET/CT can discriminate the patients with shorter progression free survival and overall survival in this pilot study, patients could be selected for more aggressive or earlier treatment such as maintenance therapy, and the investigators could expect to prolong survival while reducing the adverse events and costs that will accompany inconsequential therapy with FLT PET/CT.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- advanced non-small cell lung cancer (stage IIIB, IV)

- at least one measurable lesion

- performance status (ECOG) 0-2

- 1st-line platinum chemotherapy and no progression

Exclusion Criteria:

- mixed small cell and non-small cell

- uncontrolled brain metastasis

- previous malignancy within 5 years (except basal cell carcinoma of skin, carcinoma in situ of uterine cervix)

- pregnant or breast feeding

- pemetrexed chemotherapy
Location
Seoul St.Mary's Hospital
Seoul, Korea, Republic of
Status: Not yet recruiting
Contact: Woo Hee Choi, MD - 82-31-249-8494 - choiwoohee@gmail.com
Start Date
June 2012
Completion Date
August 2015
Sponsors
The Catholic University of Korea
Source
The Catholic University of Korea
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page